MARKET

CODX

CODX

Co-Diagnostics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.09
-0.24
-4.50%
Pre Market: 5.13 +0.04 +0.79% 08:57 06/29 EDT
OPEN
5.36
PREV CLOSE
5.33
HIGH
5.37
LOW
5.06
VOLUME
1.56K
TURNOVER
--
52 WEEK HIGH
11.82
52 WEEK LOW
3.660
MARKET CAP
173.00M
P/E (TTM)
3.917
1D
5D
1M
3M
1Y
5Y
Co-Diagnostics, Inc. to Present at 29th International Biodetection Technologies Virtual Conference
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting this week at the 29th Internatio...
PR Newswire · 1d ago
Monkeypox plays are lower as WHO rules out emergency status
The companies focused on solutions to contain the monkeypox virus are trading sharply lower in the pre-market Monday after the World Health Organization (WHO) said that the current outbreak did
Seekingalpha · 2d ago
Monkeypox is not an international health emergency yet – WHO
Following a meeting of its Emergency Committee, the World Health Organization (WHO) has decided that the current outbreak of monkeypox does not amount to a Public Health Emergency of International
Seekingalpha · 3d ago
CoDiagnostics, Inc. (CODX) Surges 5.6%: Is This an Indication of Further Gains?
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks · 5d ago
Monekeypox plays tick higher ahead of WHO emergency meeting
Companies targeting the monkeypox virus are on the rise in the pre-market Thursday as an Emergency Committee of the World Health Organization (WHO) meets today to decide whether to declare
Seekingalpha · 6d ago
22 Stocks Moving in Thursday's Pre-Market Session
Gainers WISeKey International Holding AG (NASDAQ: WKEY) rose 74.4% to $2.32 in pre-market trading. WISeKey International recently issued 2022 first-half revenue guidance for its IoT segment.
Benzinga · 6d ago
Co-Diagnostics, Inc. to Present at Sidoti Summer Small Cap Virtual Conference
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dwight Egan, CEO, Brian Brown, CFO, and Andrew Benson,...
PR Newswire · 06/15 13:30
Co-Diagnostics, Inc. to Host Booth at MEDEXPO Africa 2022 in Nairobi, Kenya on June 9-11
Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the 22nd MEDEXPO Africa ...
PR Newswire · 06/09 13:30
More
No Data
Learn about the latest financial forecast of CODX. Analyze the recent business situations of Co-Diagnostics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CODX stock price target is 18.33 with a high estimate of 29.00 and a low estimate of 12.00.
High29.00
Average18.33
Low12.00
Current 5.18
EPS
Actual
Estimate
0.100.190.280.38
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 107
Institutional Holdings: 7.48M
% Owned: 22.02%
Shares Outstanding: 33.99M
TypeInstitutionsShares
Increased
24
668.60K
New
17
634.01K
Decreased
27
1.03M
Sold Out
11
481.44K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.07%
Healthcare Equipment & Supplies
+0.35%
Key Executives
Chairman/President/Chief Executive Officer/Director
Dwight Egan
Chief Financial Officer/Secretary
Brian Brown
General Counsel
Reed Benson
Independent Director
Eugene Durenard
Independent Director
Edward Murphy
Independent Director
James Nelson
Independent Director
Richard Serbin
No Data
No Data
About CODX
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). The Company uses its proprietary test design system and proprietary reagents to design and sell polymerase chain reaction diagnostic tests for diseases and pathogens starting with tests for tuberculosis, a drug resistant tuberculosis test, hepatitis B and C, Malaria, dengue, human immunodeficiency virus and Zika virus, all of which tests have been designed and validated in its laboratory. Its diagnostics systems enable molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests.

Webull offers kinds of Co-Diagnostics Inc stock information, including NASDAQ:CODX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CODX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CODX stock methods without spending real money on the virtual paper trading platform.